Decadron (dexamethasone) / Merck (MSD) - LARVOL DELTA

Impact of Intravenous Dexamethasone on the Duration of Motor and Sensory Block Following Spinal Anesthesia With Chloroprocaine (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

New trial • Anesthesia

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Mayo Clinic | Recruiting ➔ Active, not recruiting | N=100 ➔ 16 | Trial completion date: Dec 2028 ➔ May 2027 | Trial primary completion date: Dec 2028 ➔ May 2026

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy (clinicaltrials.gov) - P2 | N=50 | Active, not recruiting | Sponsor: University of Arkansas | Trial completion date: Oct 2027 ➔ Oct 2028 | Trial primary completion date: Oct 2026 ➔ Oct 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study. (PubMed, Blood Cancer J) - "PFS was 7.5 months and OS was 19.7 months. Lenalidomide can be given at full dose 25 mg daily 21/28 in patients with a CrCl > 30, and can be given daily to those with CrCl < 30, even when on dialysis, at doses of at least 15 mg daily."

Clinical • Journal • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology • Renal Disease • Respiratory Diseases

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma. (PubMed, J Clin Oncol) - "Second AHCT or RVD consolidation as post-AHCT interventions for the up-front treatment of transplantation-eligible patients with MM did not improve PFS or OS. Single AHCT and len should remain as the standard approach for this population."

Clinical • Journal • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure (clinicaltrials.gov) - P2 | N=74 | Recruiting | Sponsor: Eastern Cooperative Oncology Group | Active, not recruiting ➔ Recruiting | Trial completion date: Feb 2027 ➔ Sep 2038 | Trial primary completion date: Feb 2027 ➔ Jan 2029

Enrollment open • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Renal Disease

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma (clinicaltrials.gov) - P3; N=288; Recruiting; Sponsor: ECOG-ACRIN Cancer Research Group; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology

CarMob: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Hackensack Meridian Health | Trial completion date: Sep 2026 ➔ Aug 2027 | Trial primary completion date: Sep 2026 ➔ Aug 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. (PubMed, Br J Cancer) - P1 | "MRX34 treatment with dexamethasone premedication demonstrated a manageable toxicity profile in most patients and some clinical activity. Although the trial was closed early due to serious immune-mediated AEs that resulted in four patient deaths, dose-dependent modulation of relevant target genes provides proof-of-concept for miRNA-based cancer therapy."

Clinical • Journal • P1 data • Fatigue • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Pain • Solid Tumor

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma (clinicaltrials.gov) - P2 | N=8 | Active, not recruiting | Sponsor: Academic and Community Cancer Research United | N=52 ➔ 8

Enrollment change • Hematological Malignancies • Multiple Myeloma • Oncology

DEXA-REFINE: Efficacy of DEXamethasone in Patients With Acute Hypoxemic REspiratory Failure Caused by INfEctions (clinicaltrials.gov) - P4 | N=980 | Completed | Sponsor: Hospital Universitario de Gran Canaria Doctor Negrín | Recruiting ➔ Completed

Trial completion • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Time to First Rescue Antiemetic With Ondansetron Plus Metoclopramide Versus Dexamethasone Plus Metoclopramide for PONV Prophylaxis in Laparoscopic Cholecystectomy (clinicaltrials.gov) - P4 | N=264 | Recruiting | Sponsor: Faisalabad Medical University | Not yet recruiting ➔ Recruiting

Enrollment open • Head-to-Head

LODEXA: Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp (clinicaltrials.gov) - P2 | N=34 | Not yet recruiting | Sponsor: University of California, San Diego

New P2 trial • Eye Cancer • Inflammation • Melanoma • Oncology • Solid Tumor • Uveal Melanoma

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma (clinicaltrials.gov) - P2 | N=34 | Recruiting | Sponsor: Emory University | Trial completion date: Oct 2027 ➔ Oct 2028 | Trial primary completion date: Oct 2026 ➔ Oct 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • CD4

FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: City of Hope Medical Center

New P1 trial • Brain Cancer • Glioblastoma • Glioma • High Grade Glioma • Oncology • Solid Tumor

AALL1631: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P3 | N=352 | Active, not recruiting | Sponsor: Children's Oncology Group | Trial primary completion date: Sep 2027 ➔ Jun 2026

Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • ABL1 • CSF1R • PDGFRA • PDGFRB

ALL Backbone in AYAs (clinicaltrials.gov) - P2 | N=67 | Recruiting | Sponsor: Dana-Farber Cancer Institute | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: Andrew Hantel, MD | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Hematological Malignancies • Multiple Myeloma • Neutropenia • Oncology • Solid Tumor • Triple Negative Breast Cancer

MCC-20130: Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - P2 | N=33 | Completed | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting ➔ Completed

Trial completion • Hematological Malignancies • Multiple Myeloma • Oncology

QUAD: A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=17 | Active, not recruiting | Sponsor: Hackensack Meridian Health | Trial completion date: Jul 2026 ➔ Jun 2027 | Trial primary completion date: Jul 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Carfilzomib, Clarithromycin (Biaxin), Lenalidomide (Revlimid), and Dexamethasone (Decadron) [Car-BiRD] Therapy for Subjects With Multiple Myeloma (clinicaltrials.gov) - P2 | N=74 | Completed | Sponsor: Weill Medical College of Cornell University | Active, not recruiting ➔ Completed | Trial completion date: Mar 2027 ➔ Mar 2026

Trial completion • Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial (clinicaltrials.gov) - P2 | N=74 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting | Initiation date: Jul 2026 ➔ Apr 2027

Enrollment open • Trial initiation date • Hematological Malignancies • Leukemia • Oncology • Plasma Cell Leukemia

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (clinicaltrials.gov) - P1/2 | N=162 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2026 ➔ Mar 2029 | Initiation date: Jul 2026 ➔ Apr 2027 | Trial primary completion date: Aug 2026 ➔ Mar 2029

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Oral Statins and Protection From Hearing Loss (clinicaltrials.gov) - P4 | N=3 | Terminated | Sponsor: Northwestern University | N=100 ➔ 3 | Recruiting ➔ Terminated; Insufficient funding

Enrollment change • Trial termination • Otorhinolaryngology